Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
Immatics Biotechnologies (Germany) · University of Tübingen · +10 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
782
total citations
- FWCI
- 40.67
- Percentile
- 100%
- References
- 71
Citations per year
Authors
39Topics & keywords
Topics
Keywords
- Medicine
- FOXP3
- Immune system
- Cyclophosphamide
- Immunology
- Oncology
- Chemokine
- Internal medicine
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.